Core Insights - Medicus Pharma Ltd. shares experienced volatility, peaking at $1.61 before declining during premarket trading following the release of Phase 2 clinical trial data for SKNJCT-003 [1] - The Phase 2 study demonstrated a 73% clinical clearance rate for Doxorubicin Microneedle Array (D-MNA) in treating basal cell carcinoma (BCC), which may facilitate an end-of-phase meeting with the FDA in the first half of 2026 [2][3] Clinical Trial Results - The topline results from the SKNJCT-003 Phase 2 clinical study indicated a 73% clinical clearance rate and a 40% histological clearance rate from a 200µg dose cohort [3] - The study involved 90 patients diagnosed with nodular basal cell carcinoma, providing decision-grade evidence of clinical activity [3] Future Plans - The company plans to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses and procedural observations [4] Stock Performance - Medicus Pharma's stock is currently trading 8.70% above its 20-day simple moving average (SMA) but is 12.5% below its 100-day SMA, indicating short-term strength and longer-term challenges [5] - Over the past 12 months, shares have significantly decreased and are closer to their 52-week lows than highs, with the current price at $1.09 during premarket trading [5][7] Technical Analysis - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [6] - The combination of neutral RSI and bearish MACD indicates mixed momentum, prompting traders to monitor potential shifts in momentum [6]
Medicus Pharma Stock Swings After Skin Cancer Treatment Results